Ergosterol biosynthesis inhibitors become fungicidal when combined with calcineurin inhibitors against Candida albicans, Candida glabrata, and Candida krusei

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 3, 2003, Pages 956-964

  Onyewu, Chiatogu ^a   Blankenship, Jill R ^a   Del Poeta, Maurizio ^b   Heitman, Joseph ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DRUG ANALOG; ERGOSTEROL; FENPROPIMORPH; FK 506 BINDING PROTEIN; FLUCONAZOLE; L 685818; METHYLTRANSFERASE; PHOSPHOPROTEIN PHOSPHATASE; PYRROLE DERIVATIVE; STEROL 14ALPHA DEMETHYLASE; TACROLIMUS; TERBINAFINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS MUTANT; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STEROL SYNTHESIS;

ANTIFUNGAL AGENTS; CALCINEURIN; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CULTURE MEDIA; DRUG SYNERGISM; ERGOSTEROL; FUNGICIDES, INDUSTRIAL; IMMUNOSUPPRESSIVE AGENTS; MICROBIAL SENSITIVITY TESTS; MORPHOLINES; MUTATION; NAPHTHALENES; OXIDOREDUCTASES; TACROLIMUS;

EID: 0345489076     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.3.956-964.2003     Document Type: Article

References (43)

1. Alrajhi, A. A., E. A. Ibrahim, E. B. De Vol, M. Khairat, R. M. Faris, and J. H. Maguire. 2002. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N. Engl. J. Med. 346:891-895.
2. Arias, A., M. P. Arevalo, A. Andreu, C. Rodriguez, and A. Sierra. 1996. Candida glabrata: in vitro susceptibility of 84 isolates to eight antifungal agents. Chemotherapy 42:107-111.
3. Becker, J. W., J. Rotonda, B. M. McKeever, H. K. Chan, A. I. Marcy, G. Wiederrecht, J. D. Hermes, and J. P. Springer. 1993. FK-506-binding protein: three-dimensional structure of the complex with the antagonist L-685,818. J. Biol. Chem. 268:11335-11339.
4. Beck-Sague, C. M., and W. R. Jarvis. 1993. Secular trends in the epidemiology of nosocomial fungal injections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167:1247-1251.
5. Benjamin, D. K., Jr., K. Ross, R. E. McKinney, Jr., D. K. Benjamin, R. Auten, and R. G. Fisher. 2000. When to suspect fungal infection in neonates: a clinical comparison of Candida albicans and Candida parapsilosis fungemia with coagulase-negative staphylococcal bacteremia. Pediatrics 106:712-718.
6. Cardenas, M. E., R. S. Muir, T. Breuder, and J. Heitman. 1995. Targets of immunophilin-immunosuppressant complexes are distinct highly conserved regions of calcineurin A. EMBO J. 14:2772-2783.
7. Cruz, M. C., A. L. Goldstein, J. Blankenship, M. Del Poeta, J. R. Perfect, J. H. McCusker, Y. L. Bennani, M. E. Cardenas, and J. Heitman. 2001. Rapamycin and less immunosuppressive analogs are toxic to Candida albicans and Cryptococcus neoformans via FKBP12-dependent inhibition of TOR. Antimicrob. Agents Chemother. 45:3162-3170.
8. Cruz, M. C., A. L. Goldstein, J. R. Blankenship, M. Del Poeta, D. Davis, M. E. Cardenas, J. R. Perfect, J. H. McCusker, and J. Heitman. 2002. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J. 21:546-559.
9. Fonzi, W. A., and M. Y. Irwin. 1993. Isogenic strain construction and gene mapping in Candida albicans. Genetics 134:717-728.
10. Fortun, J., A. Lopez-San Roman, J. J. Velasco, A. Sanchez-Sousa, E. de Vicente, J. Nuno, C. Quereda, R. Barcena, G. Monge, A. Candela, A. Honrubia, and A. Guerrero. 1997. Selection of Candida glabrata strains with reduced susceptibility to azoles in four liver transplant patients with invasive candidiasis. Eur. J. Clin. Microbiol. Infect. Dis. 16:314-318.
11. Griffith, J. P., J. L. Kim, E. E. Kim, M. D. Sintchak, J. A. Thomson, M. J. Fitzgibbon, M. A. Felming, P. R. Caron, K. Hsiao, and M. A. Navia. 1995. X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 82:507-522.
12. Hay, R. J. 1999. The management of superficial candidiasis. J. Am. Acad. Dermatol. 40:S35-S42.
13. Husain, S., M. M. Wagener, and N. Singh. 2001. Cryptococcus neoformans infection in organ transplant recipients: variables influencing clinical characteristics and outcome. Emerg. Infect. Dis. 7:375-381.
14. Jandrositz, A., F. Turnowsky, and G. Hogenauer. 1991. The gene encoding squalene epoxidase from Saccharomyces cerevisiae: cloning and characterization. Gene 107:155-160.
15. Jensen-Pergakes, K. L., M. A. Kennedy, N. D. Lees, R. Barbuch, C. Koegel, and M. Bard. 1998. Sequencing, disruption, and characterization of the Candida albicans sterol methyltransferase (ERG6) gene: drug susceptibility, studies in erg6 mutants. Antimicrob. Agents Chemother. 42:1160-1167.
16. Jia, N. 2002. Candida albicans sterol C-14 reductase, encoded by the ERG24 gene, as a potential antifungal target site. Antimicrob. Agents Chemother. 46:947-957.
17. Kawamura, A., and M. S.-S. Su. 1995. Interaction of FKBP12-FK506 with calcineurin A at the B subunit-binding domain. J. Biol. Chem. 270:15463-15466.
18. Kissinger, C. R., H. E. Parge, D. R. Knighton, C. T. Lewis, L. A. Pelletier, A. Tempczyk, V. J. Kalish, K. D. Tucker, R. E. Showalter, E. W. Moomaw, L. N. Gastinel, N. Habuka, X. Chen, F. Maldonado, J. E. Barker, R. Bacquet, and J. E. Villafranca. 1995. Crystal structures of human calcineurin and the human FKBP12-FK506-calcineurin complex. Nature 378:641-644.
19. Li, W., and R. E. Handschumacher. 1993. Specific interaction of the cyclophilin-cyclosporin complex with the B subunit of calcineurin. J. Biol. Chem. 268:14040-14044.
20. Maesaki, S., P. Marichal, M. A. Hossain, D. Sanglard, H. V. Bossche, and S. Kohno. 1998. Synergic effects of tacrolimus and azole antifungal agents against azole-resistant Candida albicans strains. J. Antimicrob. Chemother. 42:747-753.
21. Mandell, D., O. R. Cheatham, J. E. Bennett, and R. Dolin. 2000. Principles and practice of infectious diseases, 5th ed. Churchill Livingstone, Inc., Edinburgh, Scotland.
22. Marchetti, O., J. M. Entenza, D. Sanglard, J. Bille, M. P. Glauser, and P. Moreillon. 2000. Fluconazole plus cyclosporine: a fungicidal combination effective against experimental endocarditis due to Candida albicans. Antimicrob. Agents Chemother. 44:2932-2938.
23. Marchetti, O., P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard. 2000. Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans. Antimicrob. Agents Chemother. 44:2373-2381.
24. Marcireau, C., M. Guilloton, and F. Karst. 1990. In vivo effects of fenpropimorph on the yeast Saccharomyces cerevisiae and determination of the molecular basis of the antifungal property. Antimicrob. Agents Chemother 34:989-993.
25. Milan, D., J. Griffith, M. Su, E. R. Price, and F. McKeon. 1994. The latch region of calcineurin B is involved in both immunosuppressant-immunophilin complex docking and phosphatase activation. Cell 79:437-447.
26. Munro, C. A., and B. Hube. 2002. Anti-fungal therapy at the HAART of viral therapy. Trends Microbiol. 10:173-177.
27. Nghiem, P., G. Pearson, and R. G. Langley. 2002. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting calcineurin and treating atopic dermatitis. J. Am. Acad. Dermatol. 46:228-241.
28. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, D. C. Tanner, M. L. Nguyen, D. R. Snydman, M. M. Wagener, M. G. Rinaldi, and V. L. Yu. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
29. Odds, F. C. 1988. Candida and candidosis, 2nd ed. Bailliere-Tindall, London, England.
30. Odom, A., M. Del Poeta, J. Perfect, and J. Heitman. 1997. The immunosuppressant FK506 and its nonimmunosuppressive analog L-685,818 are toxic to Cryptococcus neoformans by inhibition of a common target protein. Antimicrob. Agents Chemother. 41:156-161.
31. Pfaller, M. A., R. N. Jones, G. V. Doern, H. S. Sader, R. J. Hollis, and S. A. Messer for The SENTRY Participant Group. 1998. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. J. Clin. Microbiol. 36:1886-1889.
32. Pfaller, M. A., R. N. Jones, S. A. Messer, M. B. Edmond, R. P. Wenzel et al. 1998. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn. Microbiol. Infect. Dis. 30:121-129.
33. Poutsiaka, D. D. 2001. Antimicrobial resistance in the chronically critically ill patient. Clin. Chest Med. 22:87-103.
34. Rex, J. H., M. G. Rinaldi, and M. A. Pfaller. 1995. Resistance of Candida species to fluconazole. Antimicrob. Agents Chemother. 39:1-8.
35. Rotonda, J., J. J. Burbaum, H. K. Chan, A. I. Marcy, and J. W. Becker. 1993. Improved calcineurin inhibition by yeast FKBP12-drug complexes: crystallographic and functional analysis. J. Biol. Chem. 268:7607-7609.
36. Simon, D. M., and S. Levin. 2001. Infectious complications of solid organ transplantations. Infect. Dis. Clin. N. Am. 15:521-549.
37. St-Germain, G., M. Laverdiere, R. Pelletier, A. M. Bourgault, M. Libman, C. Lemieux, and G. Noel. 2001. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J. Clin. Microbiol. 39:949-953.
38. Vanden Bossche, H. 1985. Biochemical targets for antifungal azole derivatives: hypothesis on the mode of action. Curr. Top. Med. Mycol. 1:313-351.
39. Vanden Bossche, H., G. Willemsens, and P. Marichal. 1987. Anti-Candida drugs - the biochemical basis for their activity. Crit. Rev. Microbiol. 15:57-72.
40. Venkateswarlu, K., D. W. Denning, and S. L. Kelly. 1997. Inhibition and interaction of cytochrome P450 of Candida krusei with azole antifungal drugs. J. Med. Vet. Mycol. 35:19-25.
41. Venkateswarlu, K., D. W. Denning, N. J. Manning, and S. L. Kelly. 1996. Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance. Antimicrob. Agents Chemother. 40:2443-2446.
42. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
43. Wingard, J. R., W. G. Merz, M. G. Rinaidi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone morrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.